June 13, 2022
The introduction of a four-year grace period for so-called “spillover” re-pricing in April marked a certain improvement, but more reforms need to be done for exclusion criteria for such price cuts, the Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ)...read more